NCT02278120 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 335
- group Id
- BG001
- value
- 337
- group Id
- BG002
- value
- 672
- units
- Participants
- groups
- description
- Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
- id
- BG000
- title
- Ribociclib + NSAI/Tamoxifen + Goserelin
- description
- Placebo daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days). Participants were unblinded once the final OS analysis was conducted and after the implementation of protocol amendment 6 (16-Jul-2019) and were given the option to crossover to treatment with ribociclib +NSAI/tamoxifen + goserelin
- id
- BG001
- title
- Placebo + NSAI/Tamoxifen+ Goserelin
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.6
- value
- 42.6
- group Id
- BG001
- spread
- 6.17
- value
- 43.7
- group Id
- BG002
- spread
- 6.4
- value
- 43.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 335
- group Id
- BG001
- value
- 337
- group Id
- BG002
- value
- 672
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 187
- group Id
- BG001
- value
- 201
- group Id
- BG002
- value
- 388
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 198
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 19
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 23
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 38
- title
- Unknown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 335
- group Id
- BG001
- value
- 337
- group Id
- BG002
- value
- 672
- units
- Participants
- groups
- description
- Ribociclib 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
- id
- BG000
- title
- Ribociclib + NSAI/Tamoxifen + Goserelin
- description
- Placebo daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days). Participants were unblinded once the final OS analysis was conducted and after the implementation of protocol amendment 6 (16-Jul-2019) and were given the option to crossover to treatment with ribociclib +NSAI/tamoxifen + goserelin
- id
- BG001
- title
- Placebo + NSAI/Tamoxifen+ Goserelin
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.6
- value
- 42.6
- group Id
- BG001
- spread
- 6.17
- value
- 43.7
- group Id
- BG002
- spread
- 6.4
- value
- 43.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 335
- group Id
- BG001
- value
- 337
- group Id
- BG002
- value
- 672
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 187
- group Id
- BG001
- value
- 201
- group Id
- BG002
- value
- 388
- title
- Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 198
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 19
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 16
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 23
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 38
- title
- Unknown
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle